Whole body MRI is effective for identifying metastatic disease in colorectal cancer patientsBMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l5453 (Published 27 September 2019) Cite this as: BMJ 2019;366:l5453
- Rob Cook, clinical director1,
- Peter Davidson, clinical advisor2,
- Rosie Martin, clinical specialist1
- on behalf of NIHR Dissemination Centre
- 1Bazian, Economist Intelligence Unit Healthcare, London, UK
- 2Wessex Institute, University of Southampton, Southampton, UK
- Correspondence to R Cook
Taylor S, Mallett S, Beare S et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. Lancet Gastroenterol Hepatol 2019;4:529-37.
This project was funded by the NIHR Health Technology Assessment Programme (project number 10/68/01).
To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000797/identifying-metastatic-disease-in-colorectal-cancer-with-whole-body-mri
Contributor: Fran Wilkie
All authors contributed to development and review of this summary, as part of the wider NIHR Signals editorial team. RC is guarantor.
Disclaimer NIHR Signals are owned by the Department of Health and Social Care and are made available to the BMJ under licence. NIHR Signals report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Signals.
Permission to reuse these articles should be directed to email@example.com.
Competing interests The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none
Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests